Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
34,558
datasets available to search
ShareScore release 0.9.0
Dataset results
34,558 results for “therapy”
Opportunities for targeted therapies: trametinib as a therapeutic approach to canine oral squamous cell carcinomas
Open the record for dataset details and reuse information.
An adjunctive therapy administered with an antibiotic prevents enrichment of antibiotic-resistant clones of a colonizing opportunistic pathogen
<p>Therapeutic antibiotic use drives the spread of antibiotic resistance, a major threat to public health. Ideally, clinicians could treat infections with antibiotics without fueling transmission of resistant pathogens. Here, we show proof of concept for an adjunctive therapy approach that allows treatment of target pathogens without the emergence and onward transmission of resistance. Like many of the bacterial species responsible for the antimicrobial resistance crisis, vancomycin-resistant <i>Enterococcus</i> (VRE) is a colonizing opportunistic pathogen and an important cause of drug-resistant healthcare-associated infections. VRE causes life-threatening infections in the bloodstream, but spreads via fecal-oral transmission because it asymptomatically colonizes the gastrointestinal (GI) tract. Thus, there is a physical separation between the VRE targeted by treatment (those in the blood) and the VRE contributing to onward transmission (those in the GI tract). An oral adjuvant that could eliminate or inactivate antibiotic in the GI tract would make possible intravenous patient treatment without promoting transmissible resistance. We tested this idea in a mouse model of VRE GI tract colonization using cholestyramine, which we show binds daptomycin, one of the few remaining front-line antibiotics against VRE. Adjunctive cholestyramine therapy reduced the fecal shedding of daptomycin-resistant VRE by up to 80-fold in mice treated with daptomycin. These results provide proof-of-concept for an approach that could reduce the spread of antibiotic resistance for many important hospital pathogens.</p>
Data from: Scrambler therapy improves pain in neuromyelitis optica: a randomized controlled trial
<p>Objective: The primary objective aimed to determine if Scrambler therapy is an effective, acceptable and feasible treatment of persistent central neuropathic pain in patients with neuromyelitis optica spectrum disorder (NMOSD). The secondary objective explored the effect of Scrambler therapy on co-occurring symptoms.</p> <p>Methods: We conducted a randomized single blind, sham-controlled trial in patients with NMOSD who have central neuropathic pain using Scrambler therapy for 10 consecutive weekdays. Pain severity, pain interference, anxiety, depression and sleep disturbance were assessed at baseline, end of treatment, and at 30- and 60-day follow-up.</p> <p>Results: Twenty-two patients (11 per arm) were enrolled into and completed this trial. The median baseline NRS pain score decreased from 5.0 to 1.5 following 10 days of treatment with Scrambler therapy, whereas the median NRS score did not significantly decrease in the sham arm. Depression was also reduced in the treatment arm, and anxiety was decreased in a subset of patients who responded to treatment. These symptoms were not impacted in the sham arm. The safety profiles were similar between groups.</p> <p>Conclusions: Scrambler therapy is an effective, feasible and safe intervention for central neuropathic pain in patients with NMOSD. Decreasing pain with Scrambler therapy may additionally improve depression and anxiety. Clinicaltrials.gov identifier NCT03452176 Classification of Evidence This study provides Class II evidence for patients with NMOSD and persistent central neuropathic pain that Scrambler therapy significantly reduces pain.</p>
Single-cell profiling identifies pre-existing CD19-negative subclones in a B-ALL patient with CD19-negative relapse after CAR-T therapy
<p>This repository contains necessary files for reproducing the analysis in Rabilloud, Potier et al. (2020). The instructions for reproducing the analysis are given in github (https://github.com/Delphine-Potier/B-ALL-CAR-T) and extra files are available in GEO/SRA (GSE153697 ; SRP269742).</p>
Data from: Initiating Antiretroviral Therapy for HIV at a Patient's First Clinic Visit: The RapIT Randomized Controlled Trial
<p><strong>Background:</strong> High rates of patient attrition from care between HIV testing and antiretroviral therapy (ART) initiation have been documented in sub-Saharan Africa, contributing to persistently low CD4 cell counts at treatment initiation. One reason for this is that starting ART in many countries is a lengthy and burdensome process, imposing long waits and multiple clinic visits on patients. We estimated the effect on uptake of ART and viral suppression of an accelerated initiation algorithm that allowed treatment-eligible patients to be dispensed their first supply of antiretroviral medications on the day of their first HIV-related clinic visit.</p> <p><strong>Methods and Findings: </strong>RapIT was an unblinded randomized controlled trial of single-visit ART initiation in two public sector clinics in South Africa (a primary health clinic (PHC) and a hospital-based HIV clinic). Adult (≥18), non-pregnant patients receiving a positive HIV test or first treatment-eligible CD4 count were randomized to standard or rapid initiation. Rapid arm patients received a point-of-care (POC) CD4 count if needed; those ART-eligible received a POC TB test if symptomatic, POC blood tests, physical exam, education, counseling, and ARV dispensing. Standard arm patients followed standard clinic procedures (3-5 additional clinic visits over 2-4 weeks prior to ARV dispensing). Follow up was by record review only. The primary outcome was viral suppression, defined as initiated, retained in care, and suppressed (<=400 copies/ml) ≤ 10 months of study enrollment. Secondary outcomes included initiation of ART ≤ 90 days of study enrollment; retention in care; time to ART initiation; patient-level predictors of primary outcomes; prevalence of TB symptoms; and the feasibility and acceptability of the intervention. A survival analysis was conducted comparing attrition from care after ART initiation between the groups among those who initiated within 90 days. 377 patients were enrolled in the study between May 8, 2013 and August 29, 2014 (median CD4 count 210 cells/mm<sup>3</sup>). In the rapid arm, 119/187 patients (64%) initiated and were suppressed at 10 months, compared to 96/190 (51%) in the standard arm (RR 1.26 [1.05-1.50]. In the rapid arm 182/187 (97%) initiated ART ≤ 90 days, compared to 136/190 (72%) in the standard arm (relative risk [95% CI] 1.36 [1.24-1.49]. Among 318 patients who did initiate ART within 90 days, the hazard of attrition within the first 10 months did not differ between the treatment arms (HR 1.06; 95% CI 0.61-1.84). The study was limited by the small number of sites and small sample size and the generalizability of the results to other settings and to non-research conditions is uncertain.</p> <p><strong>Conclusions: </strong>Offering single-visit ART initiation to adult patients in South Africa increased uptake of ART by 36% and viral suppression by 26%. It should be considered for adoption in the public sector in Africa.</p>
Effectiveness of steroid therapy on pneumonic chronic obstructive pulmonary disease exacerbation: a multi-centred retrospective cohort study
<p><span>Background</span></p> <p><span>To date, no consensus exists on the effects of steroid use on pneumonic chronic obstructive pulmonary disease (COPD) owing to trial design issues in previous trials involving these conditions. Therefore, we aimed to evaluate steroid effectiveness in pneumonic COPD exacerbation patients.</span></p> <p><span>Methods</span></p> <p><span>This multi-centred, retrospective, observational study was conducted across five acute general hospitals in Japan. We analysed the association between parenteral/oral steroid therapy and time to clinical stability in pneumonic COPD exacerbation. </span></p> <p><span>We used a validated algorithm derived from the 10th revision of the International Classification of Diseases and Related Health Problems (ICD-10) to include pneumonic COPD exacerbation patients. We excluded patients with other hypoxia causes (asthma exacerbation, pneumothorax, heart failure) and complicated pneumonia (obstructive pneumonia, empyema), those who required tracheal intubation/vasopressors, and those who were clinically stable on the admission day. </span></p> <p><span>The primary outcome was time to clinical stability. Multiple imputation was used for missing data. Propensity scores within each imputed dataset were calculated using potential confounding factors. The Fine and Gray model was used within each dataset to account for the competing risk of death and hospital discharge without clinical stability, and we combined the results.</span></p> <p><span>Results</span></p> <p><span>Altogether, 1237 patients were included. The pooled estimated subdistribution hazard ratio of time to clinical stability in steroid versus non-steroid users was 0.89 (95% confidence interval, 0.78<a name="_Hlk33128668"> to</a> 1.03). However, there were potentially unmeasured confounders, and we could not assess longer-term outcomes.</span></p> <p><span>Conclusions</span></p> <p><span>The current study recommends that steroid therapy should not be used routinely for pneumonic COPD exacerbation.</span></p>
Data from: Optimizing prevention of HIV mother to child transmission: duration of antiretroviral therapy and viral suppression at delivery among pregnant Malawian women
Background: Effective antiretroviral therapy during pregnancy minimizes the risk of vertical HIV transmission. Some women present late in their pregnancy for first antenatal visit; whether these women achieve viral suppression by delivery and how suppression varies with time on ART is unclear. Methods: We conducted a prospective cohort study of HIV-infected pregnant women initiating antiretroviral therapy for the first time from June 2015 to November 2016. Multivariable Poisson models with robust variance estimators were used to estimate risk ratios (RR) and 95% confidence intervals (CI) of the association between duration of ART and both viral load (VL) ≥1000 copies/ml and VL ≥40 copies/ml at delivery. Results: Of the 252 women who had viral load testing at delivery, 40 (16%) and 78 (31%) had VL ≥1000 copies/ml and VL ≥40 copies/ml, respectively. The proportion of women with poor adherence to ART was higher among women who were on ART for ≤12 weeks (9/50 = 18.0%) than among those who were on ART for 13-35 weeks (18/194 = 9.3%). Compared to women who were on ART for ≤12 weeks, women who were on ART for 13-20 weeks (RR = 0.52; 95% CI: 0.36-0.74) or 21-35 weeks (RR = 0.26; 95% CI: 0.14-0.48) had a lower risk of VL ≥40 copies/ml at delivery. Similar comparisons for VL ≥1000 copies/ml at delivery showed decrease in risk although not significant for those on ART 13-20 weeks. Conclusion: Longer duration of ART during pregnancy was associated with suppressed viral load at delivery. Early ANC attendance in pregnancy to facilitate prompt ART initiation for HIV-positive women is essential in the effort to eliminate HIV vertical transmission.
Data from: A single session of hyperbaric oxygen therapy demonstrates acute and long-lasting neuroplasticity effects in humans: a replicated, randomized controlled clinical trial
Purpose: Animal studies have demonstrated anti-inflammatory, and anti-nociceptive properties of hyperbaric oxygen therapy (HBOT). However, physiological data are scarce in humans. In a recent experimental study, the authors used the burn injury (BI) model observing a decrease in secondary hyperalgesia area (SHA) in the HBOT-group compared to a control-group.Surprisingly, a long-lasting neuroplasticity effect mitigating the BI-induced SHA-response was seen in the HBOT-preconditioned group. The objective of the present study, therefore, was to confirm our previous findings using an examiner-blinded, block-randomized, controlled, crossover study design. Patients and methods: Nineteen healthy subjects attended two BI-sessions with an inter-session interval of ≥28 days. The BIs were induced on the lower legs by a contact thermode (12.5 cm2, 47C°, 420 s). The subjects were block-randomized to receive HBOT (2.4 ATA, 100% O2, 90 min) or ambient conditions ([AC]; 1 ATA, 21% O2), dividing cohorts equally into two sequence allocations: HBOT-AC or AC-HBOT. All sensory assessments performed during baseline, BI, and post-intervention phases were at homologous time points irrespective of sequence allocation. The primary outcome was SHA, comparing interventions and sequence allocations. Data are mean (95% CI). Results: During HBOT-sessions a mitigating effect on SHAs was demonstrated compared to AC-sessions, ie, 18.8 (10.5–27.0) cm2 vs 32.0 (20.1–43.9) cm2 (P=0.021), respectively. In subjects allocated to the sequence AC-HBOT a significantly larger mean difference in SHA in the AC-session vs the HBOT-session was seen 25.0 (5.4–44.7) cm2 (P=0.019). In subjects allocated to the reverse sequence, HBOT-AC, no difference in SHA between sessions was observed (P=0.55), confirming a preconditioning, long-lasting (≥28 days) effect of HBOT. Conclusion: Our data demonstrate that a single HBOT-session compared to control is associated with both acute and long-lasting mitigating effects on BI-induced SHA, confirming central anti-inflammatory, neuroplasticity effects of hyperbaric oxygen therapy.
Data from: D quantification of tumor vasculature in lymphoma xenografts in NOD/SCID mice allows to detect differences among vascular-targeted therapies
Quantitative characterization of the in vivo effects of vascular-targeted therapies on tumor vessels is hampered by the absence of useful 3D vascular network descriptors aside from microvessel density. In this study, we extended the quantification of planar vessel distribution to the analysis of vascular volumes by studying the effects of antiangiogenic (sorafenib and sunitinib) or antivascular (combretastatin A4 phosphate) treatments on the quantity and spatial distributions of thin microvessels. These observations were restricted to perinecrotic areas of treated human multiple myeloma tumors xenografted in immunodeficient mice and to microvessels with an approximate cross-sectional area lower than 75 µm2. Finally, vessel skeletonization minimized artifacts due to possible differential wall staining and allowed a comparison of the various treatment effects. Antiangiogenic drug treatment reduced the number of vessels of every caliber (at least 2-fold fewer vessels vs. controls; p<0.001, n = 8) and caused a heterogeneous distribution of the remaining vessels. In contrast, the effects of combretastatin A4 phosphate mainly appeared to be restricted to a homogeneous reduction in the number of thin microvessels (not more than 2-fold less vs. controls; p<0.001, n = 8) with marginal effects on spatial distribution. Unexpectedly, these results also highlighted a strict relationship between microvessel quantity, distribution and cross-sectional area. Treatment-specific changes in the curves describing this relationship were consistent with the effects ascribed to the different drugs. This finding suggests that our results can highlight differences among vascular-targeted therapies, providing hints on the processes underlying sample vascularization together with the detailed characterization of a pathological vascular tree.
Data from: Probabilistic interfractional motion carbon ion radiation therapy dose distribution for prostate cancer shows rectum sparing with moderate target coverage degradation
Purpose: This observational study investigates the influence of interfractional motion on clinical target volume (CTV) coverage, planning target volume (PTV) margins, and rectum tissue sparing in carbon ion radiation therapy (CIRT). It reports dose coverage to target structures and organs at risk in the presence of interfractional motion, investigates rectal tissue sparing, and provides recommendations for further lowering the rate of toxicity. We also propose probabilistic DVH for consideration in treatment planning to represent probable dose to the clinic's patient population. Methods: At Gunma University Hospital intensity-modulated x-ray therapy (IMXT, aka IMRT) prostate cancer patients are positioned on a table which is shifted twice based on cone-beam computed tomography (CBCT) to align bones and then align prostate tissue to isocenter. These shifts thereby contain interfractional motion. 1306 such tableshifts from 85 patients were collected. Normal probability distributions were fit to the difference between bone-matching and prostate-matching CBCT-to-planning CT tableshifts (i.e. interfractional motion). Between 2011 and 2016 CIRT prostate patients were treated with PTV1 and PTV2 margins as follows: PTV1 extends the prostate contour by 10/10, 5/10, 6/6 mm in the right/left, posterior/anterior, and superior/inferior directions, respectively, and the proximal seminal vesicles contour by 5 mm superiorly and inferiorly, 3 mm right and left. PTV2 reduces PTV1 posteriorly along a straight line to exclude the rectum and reduces the superior and inferior margins by 6 mm. From those treated with these margins, 40 patients' beam data were selected to create probable interfractional motion: The previously fit normal probability distributions were randomly sampled 2000 times per patient and beams shifted to simulate this motion. These shifted dose distributions were scaled down proportionately in magnitude and summed to obtain probable blurred dose distributions. Results: Probable dose to rectum is substantially less than planned for doses higher than 10 Gy(RBE). Absolute DVH show that mean clinical target volumes are about 138-670 cm3 smaller for a given probable dose than planned doses higher than 57 Gy(RBE) after accounting for standard error. Cumulative DVH show mean CTV fraction receiving a given probable dose is less than the mean fraction receiving the corresponding planned dose for doses larger than 52 Gy(RBE), up to 19% less at 57.4 Gy(RBE). Our PTV1 margins generally cover 95% of interfractional motion but seminal vesicles and inferior prostate receive less dose than planned due to insufficient PTV2 margins. Conclusion: Assuming rigidly shifting interfractional motion around the prostate region and neglecting minor changes in soft tissue stopping power, interfractional motion resulted in underdosing or tissue sparing in all cases. Given our low rates of relapse and recurrence, it appears less curative dose is needed than previously thought or else the target may be smaller than previously thought. In-room CT may be useful to lower dose, shrink target margins, conduct PET auto-activation dose verification studies and account for interfractional motion.
Data from: Long-term benefit of hepatitis C therapy in a safety net hospital system: a cross-sectional study with median 5-year follow-up
Objectives: To demonstrate the effectiveness of hepatitis C virus (HCV) therapy and survival benefit from sustained virologic remission (SVR) in a safety net hospital population with limited resources. Design and setting: We conducted a retrospective cross-sectional study at an urban safety-net hospital in the U.S. Participants and intervention: 242 patients receiving standard HCV therapy between 2001 and 2006. Primary and secondary outcome measures: Response rates, including sustained virologic response (SVR), were recorded for each patient. Univariate and multivariate analyses were performed to identify predictors of SVR and 5 year survival. Results: A total of 242 eligible patients were treated. Treatment was completed in 197 (81%) patients, with 43 patients discontinuing therapy early – 32 due to adverse events and 11 due to non-compliance. Complications on treatment were frequent, including 3 deaths. SVR was achieved in 83 patients (34%). On multivariate analysis, independent predictors of a decreased likelihood of achieving SVR included African American race (OR 0.20, 95% CI 0.07 – 0.54), genotype 1 HCV infection (OR 0.25, 95% CI 0.13 – 0.50) and the presence of cirrhosis (OR 0.26, 95% CI 0.12 – 0.58). Survival was 98% in those achieving SVR (median follow-up 72 months) and 71% in non-responders and those discontinuing therapy (n = 91, median known follow-up 65 and 36 months respectively). On multivariate analysis, the only independent predictor of improved survival was SVR (HR 0.12, 95% CI 0.03 – 0.52). Both cirrhosis and hypoalbuminemia were independent predictors of increased mortality. Conclusions: HCV therapy can be effective despite limited resources. Survival is improved in those achieving SVR. Treatment before histologic cirrhosis develops, in combination with careful selection, may improve long-term outcomes without compromising other health care endeavors in safety net hospitals and areas with financial limitations.
Multidirectional Effects of Red Clover (Trifolium pratense L.) in Support of Menopause Therapy
<p>Data includes source data and the publication to which it is related</p>
Multi-Omic Single-Cell Dissection of Leukemic T-Cell Lymphoma Following CAR T-Cell Therapy
<p>This repository contains code used to produce the results in: Till Braun, Michael Rade and Maximilian Merz et al., Multi-Omic Single-Cell Dissection of Leukemic T-Cell Lymphoma Following CAR T-Cell Therapy</p> <p>Contents:<br>- Instructions for using the singularity image and R packages can be found here: <a href="https://github.com/fraunhofer-izi/Braun_et_al_2024/tree/main/singularity">https://github.com/fraunhofer-izi/Braun_et_al_2024/tree/main/singularity</a><br>- "seurat_harmony.Rds" and "seurat_harmony_t.Rds": These Seurat objects were used to produce Figure 2 in this publication. "seurat_tcell_obj.Rds" is a subset of "seurat_harmony.Rds" and contains only T-cells. In addition, the metadata was extended by the output of TCR-Seq (using the R package scRepertoire). The following script uses the objects: <a href="https://github.com/fraunhofer-izi/Braun_et_al_2024/blob/main/publication/figure_scripts/main/fig_02.R">https://github.com/fraunhofer-izi/Braun_et_al_2024/blob/main/publication/figure_scripts/main/fig_02.R</a></p> <p> </p>
Dataset for Effects Effects of Soft Tissue Mobilization with TECAR Therapy Using Bracelet Electrodes in Women with Chronic Non-specific Neck Pain
<p>This dataset contains anonymized data from a randomized controlled trial (RCT) evaluating the effectiveness of combining Soft Tissue Mobilization Techniques (STMT) with Capacitive and Resistive Electric Transfer Therapy (TECAR) in women with Chronic Non-Specific Neck Pain (CNSNP). Data include assessments at baseline, the 5th week, and the 6th-month follow-up for variables related to pain intensity, disability, and range of motion (ROM).</p>
mock interview with caretaker for ABA based pediatric feeding therapy
<p>cover all the basis: variety, volume, reinforcers, termination of meals, meal location, feeder, self or nonself feeder, texture, medical background... </p>
Raw data for "Preclinical upper- limb neurorobotic platform to assess, rehabilitate and develop therapies"
<p>Source data for all figures. Tabulated data underlying the data points in all plots of each individual figure.</p>
Supplemental material for: Clinical and neuroimaging outcomes of direct endovascular thrombectomy vs. bridging therapy in large vessel occlusion patients: a secondary analysis of SELECT cohort study
<p><b>Objective:</b> To evaluate the comparative safety and efficacy of direct endovascular thrombectomy(dEVT) compared to bridging therapy(BT:IV-tPA+EVT) and assess if BT potential benefit relates to stroke severity, size and initial presentation to EVT vs. non-EVT center.</p> <p><b>Methods:</b> In a prospective multicenter cohort-study of imaging selection for endovascular thrombectomy[SELECT], anterior-circulation large vessel occlusion (LVO) patients presenting to EVT-capable centers within 4.5hours from last-known-well were stratified into BT vs. dEVT.<b><i> </i></b>The primary outcome was 90-day functional independence[modified Rankin Scale(mRS)=0-2]. Secondary outcomes included a shift across 90-day mRS grades, mortality, symptomatic intracranial hemorrhage. We also performed subgroup-analyses according to initial presentation to EVT-capable center (direct versus transfer), stroke severity and baseline infarct core volume.</p> <p><b>Results:</b> We identified 226 LVOs (54%:men, mean age:65.6±14.6years, median NIHSS-score: 17, 28% received dEVT). Median time from arrival to groin-puncture did not differ in BT-patients when presenting directly[dEVT:1.43 (IQR=1.13-1.90) hours vs. BT:1.58(IQR=1.27-2.02)hours,p=0.40] or transferred to EVT-capable centers[dEVT:1.17 (IQR: 0.90-1.48) hours vs. BT:1.27 (IQR: 0.97-1.87) hours,p=0.24]. BT was associated with higher odds of 90-day functional independence (57% vs. 44%,aOR=2.02,95%CI:1.01-4.03,p=0.046) and functional improvement (adjusted cOR=2.06,95%CI:1.18-3.60,p=0.011), and lower likelihood of 90-day mortality (11% vs. 23%,aOR: 0.20,95%CI:0.07-0.58,p=0.003). No differences in any other outcomes were detected. In subgroup-analyses, BT patients with baseline NIHSS-scores<15 had higher functional independence likelihood compared to dEVT (aOR=4.87,95%CI:1.56-15.18,p=0.006); this association was not evident for patients with NIHSS-scores≥15 (aOR=1.05,95%CI:0.40-2.74,p=0.92). Similarly, functional outcomes improvements with BT were detected in patients with core volume strata (Ischemic core <50cc: aOR: 2.10, 95% CI:1.02-4.33, p=0.044 vs ischemic core ≥50cc: aOR: 0.41,95% CI:0.01-16.02,p=0.64) and transfer status (transferred: aOR: 2.21,95% CI:0.93-9.65,p=0.29 vs direct to EVT center: aOR:1.84,95%CI:0.80-4.23,p=0.15). </p> <p><b>Conclusions:</b> Bridging therapy appears to be associated with better clinical outcomes, especially with milder NIHSS-scores, smaller presentation core volumes and those who were "dripped and shipped".</p> <p><b>Classification of Evidence: </b>This study provides Class III evidence that for patients with ischemic stroke from anterior-circulation LVO within 4.5 hours from last-known-well, bridging therapy compared to direct endovascular thrombectomy leads to better 90-day functional outcomes.</p>
Saccharomyces boulardii in addition to antofloxacin-based bismuth quadruple therapy for Helicobacter pylori eradication
<p><em>Hpylori</em> is a gram-negative bacterium colonized in gastric mucosa. Currently, the infection rate of <em>H. pylori</em> in China is about 50%, which is not only closely related to a variety of digestive system diseases, but also induces a series of immune responses to other systems.</p>
Saccharomyces boulardii in addition to antofloxacin-based bismuth quadruple therapy for Helicobacter pylori eradication
<p><em>Hpylori</em> is a gram-negative bacterium colonized in gastric mucosa. Currently, the infection rate of <em>H. pylori</em> in China is about 50%, which is not only closely related to a variety of digestive system diseases, but also induces a series of immune responses to other systems.</p>
AAV gene therapy encoding equine IL10
<p>Equine recurrent uveitis (ERU) is a spontaneous, painful, and vision threatening disease affecting up to 25% of equine populations worldwide. Current treatments of ERU are non-specific and have many side effects which limits them to short-term use. In order to develop an effective therapy for ERU, we investigated the use of adeno-associated virus (AAV) gene therapy, exploiting a natural immune tolerance mechanism induced by equine interleukin-10 (Equine-IL10). The purpose of this study was to evaluate the therapeutic efficacy of a single intravitreal (IVT) dose of AAV8-Equine-IL10 gene therapy for inhibition of experimental autoimmune uveitis (EAU) in rats. Each rat was dosed intravitreally (IVT) in both eyes with either balanced salt solution (BSS) (control; n=4), AAV8-Equine-IL10 at a low dose (2.4x10<sup>9</sup> vg; n=5) or high dose (2.4x10<sup>10</sup> vg; n=5). EAU was induced in all groups of rats 7 days after IVT injections and euthanized 21 days post-injection. Ophthalmic examination and aqueous humor (AH) cell counts were recorded with the observer blinded to the treatment groups. Histopathology and qPCR were performed on selected ocular tissues. Data presented herein demonstrate that AAV8-Equine-IL10 treated rats exhibited a significant decrease in clinical inflammatory scores and AH cell counts compared to BSS-treated EAU eyes on days 10, 12 and 14 post EAU induction at both administered vector doses. Mean cellular histologic infiltrative scores were also significantly less in AAV8-Equine-IL10 dosed rats compared to the BSS group. Intravitreal injection of AAV8-Equine-IL10 resulted in Equine-IL10 cDNA expression in the ciliary body, retina, cornea, and optic nerve in a dose-dependent manner. A single IVT injection of AAV8-Equine-IL10 appeared to be well-tolerated and inhibited EAU even at the lowest administered dose. These results demonstrate safety and efficacy of AAV8-Equine-IL10 to prevent EAU and support continued exploration of AAV gene therapy for the treatment of equine and perhaps human recurrent uveitis.</p>
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.